Cipla Limited executed a block deal worth approximately INR 35.7 crore on the NSE, selling around 251,702 shares at INR 1,417 apiece.

Cipla's stock has seen a two-day increase following its earnings release, indicating robust momentum and drawing market interest.

Pharmaceutical company Cipla and telecom giant Bharti Airtel experienced rallies following their results releases, while Balaji Amines and NLC India demonstrated strong upward trends. The Bombay Stock Exchange (BSE) exceeded 4000, with MTAR Tech's gains maintaining momentum, prompting investors to ponder buy or sell decisions.

Investment firm Equirus Securities recommends buying shares of Cipla with the current market price at ₹1,438.65. They believe that Cipla is a good investment choice.

Today, shares of Cipla experienced a substantial increase, earning it the title of "Hero of the Day". Notable points from their conference call, as reported by Nupurkunia, indicated a positive outlook for the company.

Cipla aims to achieve a $1 billion annual revenue from their North American operations by fiscal year 2027, fueled by upcoming product launches with growth anticipated in the second half of this year, except for Lanreotide.

Today, Cipla witnessed a significant surge of 6.3%, leading the top performers among large-cap stocks. On the contrary, Tube Investments faced a 4.6% dip in its share price. However, it's worth noting that decliners outnumbered gainers with an advance-decline ratio of 0.74x, indicating a challenging day for the market.

Despite a mixed performance in Q4 FY26, brokerages remain optimistic about Cipla's long-term growth prospects, projecting a potential 22% increase in the stock price.

Cipla, in response to escalating freight and fuel prices due to tensions in West Asia, is working diligently to maintain a steady supply of their drugs while navigating these financial hurdles.

Cipla's impressive results and positive management commentary could lead to potential gains in the stock price. Investors should keep an eye out for any further developments. A 3% drop in Paytm's shares was observed due to speculations about a block deal, with investors advised to observe post-deal activity for potential buying opportunities.

Achin Gupta, CEO of Cipla, highlights the importance of securing drug supplies to maintain a steady flow of essential medicines and address potential shortages.

Brokerages have issued new ratings for TVS Motor, Cipla, Airtel, HPCL, and Crompton Greaves, showing a mix of optimism and caution. Highlights include TVS Motor's strong Q4 performance, continued growth for Cipla in India, refining gains for HPCL, and robust mobile and Africa growth for Airtel.

Cipla aims to enhance profit margins by focusing on internal respiratory treatments and chronic therapies, along with cost-cutting measures. However, geopolitical fluctuations could potentially introduce short-term volatility, notwithstanding the improved margin profile and operational efforts.

Morgan Stanley continues to advise against investing heavily in Cipla, setting its price target at ₹1,218. Investors may want to consider looking elsewhere for potential gains.

Nuvama has moved its recommendation for Cipla from 'Reduce' to 'Buy', indicating a positive outlook. The target price for the pharmaceutical company has been increased to ₹1,550, suggesting potential growth ahead.

HSBC continues to recommend holding Cipla shares, setting a target price of ₹1340. The recommendation comes after Cipla missed Q4FY26 targets, with earnings dependent on Lanreotide supply for future profitability and growth in US sales reliant on new product launches.

Cipla aims to achieve EBITDA margins of 18.5-20% by FY27, with growth expected in the second half of this fiscal year. Notably, the projection does not account for Lanreotide's contribution, as indicated in a recent conference call update.

Cipla's exec reports difficulties transporting goods to the Middle East due to logistical issues, potentially impacting their operations in the region.

Despite a significant drop in Q4 profits by 55%, Cipla's shares have surged by 2.7%. This could be due to the company's strategic focus on expanding its biosimilars pipeline, aiming for consistent product growth over the next five to six years. Notably, the India business has shown a robust 15% year-on-year growth.

Cipla receives an 'Overweight' rating from JPMorgan, with a target price of ₹1550. The upgrade is based on a robust US pipeline, strong future revenue projections in the US, and undervaluation compared to industry peers.

Citi maintains a positive outlook for Cipla, increasing its target price to ₹1,700. Investors are encouraged to consider buying shares in the pharmaceutical company, as per Citi's latest recommendation.

The Nifty index surpassed 23,500 today, with notable contributions from Cipla, Bharti Airtel, Sun Pharma, Adani Ports, and Bajaj Auto, among others. Notably, the pharmaceutical sector demonstrated strong performance within sectoral indices. Additionally, an advance-decline ratio of 5:1 was observed, signaling more stocks advancing than declining.

Analysts from various brokerages have weighed in on Cipla's Q4 results, offering their insights and expectations for the future. Their reports suggest a mixed response to the pharmaceutical company's performance during the last quarter.

Cipla's shares surged by 7%, following robust Q4 results and a positive forecast for its US business. JPMorgan boosted their outlook to 'Overweight', setting a new target of ₹1,550. Additionally, Citi raised its target to ₹1,700 due to anticipated India growth, a promising product pipeline, and FY27 EBITDA margin guidance of 18.5%-20%. Despite this optimism, HSBC remains cautious with a 'Hold' rating at ₹1,340.

Mitessh Thakkar recommends investing in stocks like Cipla, Hindalco, and Manappuram Finance. However, he suggests temporarily selling off Eicher Motors due to its current market status.

Cipla Ltd. recently executed a large trade worth INR 15.9 crore, selling 111,354 shares at approximately INR 1,429 each on the National Stock Exchange (NSE).

Cipla anticipates robust double-digit expansion in their Indian operations by financial years 2027-2028, aiming to surpass market growth by capitalizing on recent positive trends.

Cipla is dealing with increased costs due to the Iran crisis, but the company has mitigated some of these impacts through strategic inventory management, optimizing freight costs, and adjusting supply sources from the Middle East.

Cipla's US revenue took a hit due to decreased sales of its drugs Revlimid and Lanreotide in the North American market. This decline in sales has adversely affected Cipla's performance in the region.

Anticipation builds as Cipla prepares to announce Q4 earnings, with industry indicators suggesting a potential decrease in performance compared to previous quarters. Insights from Meryl offer valuable perspectives ahead of the release. (ET Now)

Cipla plans to introduce eight new peptide drugs and complex generics in their fiscal years 2027 and 2028, with their North America division taking the lead. Three additional assets are anticipated to be submitted over the next year and a half.

In Cipla's latest quarterly report, notable successes and areas for improvement are evident, according to ET NOW. The pharmaceutical company has seen some significant achievements, but there are also aspects that require attention.

The Nifty has dropped by over 1,100 points in the past four trading days, breaching the significant 23,500 support level. Notably, this downward trend impacts sectors like jewelry, with key players such as Cipla, Dixon, Bharti Airtel, and HPCL reporting their results.

Today's focus is on Bharti Airtel and Cipla, along with PFC, HPCL, and NALCO as they announce their Q4 results. These companies' performance could potentially influence market movements significantly. Keep an eye on these stocks for potential volatility.

Today, Bharti Airtel and Cipla will announce their Q4 earnings. Notable changes include CLSA revising Dixon's target price down to Rs 10,400, while HSBC has initiated a buy recommendation for SRF at Rs 3,390. The moves by Dr Reddy's and Dixon in response to results remain to be seen.

Cipla's India operations posted a robust 15% year-on-year growth, driven by strong performance across segments. However, the company experienced a significant 26% decline in Q4 revenue from North America. Meanwhile, Africa demonstrated impressive quarterly and annual growth rates of 21% and 12%, respectively. For FY26, the total revenue amounted to INR 28,163 Cr with a profit after tax (PAT) of INR 3,879 Cr, according to ScoutQuest's report.

Cipla's Q4 results for the financial year 2026 are set to be released on May 13, with expectations of stagnant revenues due to challenges in the US market affecting the short-term outlook. Analysts at Motilal Oswal and ICICI predict a decline in EBITDA margins but highlight the company's respiratory pipeline as a key focus area.

Pharmaceutical company, Cipla, announces a dividend payout of INR 13 per share following a decision made by their board of directors.

Anticipated earnings for Cipla in Q4FY26, according to ET Now, highlight crucial projections. For further insights on their Q4 results, visit the provided link.

HPCL's shares soar due to impressive financial performance, potentially signaling an increase in fuel prices. On the other hand, Cipla's stocks climb despite underperforming earnings, possibly due to heavy short position closures.